• BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., said that it will embark on two new Phase III efficacy trials of LibiGel, a testosterone therapy for female sexual dysfunction, and that it will continue ongoing LibiGel Phase III cardiovascular and breast cancer safety studies.